Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

GlobalData: Late-Stage Prostate Cancer Pipeline Holds Promise for Future

Although options for prostate cancer have historically been limited, the late-stage prostate cancer pipeline holds promise for the future of this second most common cancer among men, according to Glob...

AstraZeneca Announced Positive Results from Phase III Trial of Tagrisso

astrazeneca
AstraZeneca announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patient...

FDA Granted Breakthrough Therapy Designation for Bempegaldesleukin

Nektar Therapeutics and Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-2...

AstraZeneca and MSD’s Announced Positive Results from the Phase III Trial of Lynparza

preclinical-research
AstraZeneca and MSD Inc., Kenilworth, N.J., US announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) w...

Aquinox and Neoleukin Announced Merger Agreement

Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc., a privately-held biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announc...

Innovent & Shenogen to Evaluate Combo for the Treatment of Patients with Advanced Cancer

drug-development
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced the signing of a collaboration agreement with Shenogen Pharma Group...

FDA Granted Approval to Daiichi Sankyo’s Turalio

The U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with seve...

Mylan & Biocon Launched Ogivri™, a Biosimilar to Herceptin®, in Australia

Biocon Ltd. and Mylan N.V. announced the launch in Australia of Ogivri™ (trastuzumab), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic s...

Alligator Bioscience Regained Exclusive Rights for CD40 from Janssen Biotech

Alligator Bioscience announced that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop and commercialize the CD40 agonistic antibody, ADC-1013 (JNJ-64457107), its lead tu...

AstraZeneca’s Lynparza to be Funded through UK’s Cancer Drugs Fund

astrazeneca
A "game-changing" ovarian cancer drug that can extend lives by delaying or even preventing the disease recurring is now being made available on the NHS. Lymparza (olaparib) could offer a cure for some...

FDA Approved RUXIENCE™ for the Treatment of Patients with non-Hodgkin’s Lymphoma

pfizer
Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients wit...

Anixa Biosciences to Develop Innovative Breast Cancer Vaccine Technology with Cleveland Clinic

cancer treatment
Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body's immune system to fight cancer, announced that it has established a strategic alliance and license agreement with Cleve...

GlobalData Forecast: B-cell NHL Market Will Reach $9.2bn by 2027

The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets at a compound annual growth rate (CAGR) of 4.9%, according to Gl...

IBTC Announced Partnership with Karyopharm to Accelerate Treatment of Brain Cancer

cancer drugs
The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics to accelerate the treatment of brain cancer. The Ivy Brain Tumor Center will em...

SMC Recommended Janssen’s Darzalex for Multiple Myeloma Treatment

The Scottish Medicines Consortium (SMC) has recommended Darzalex® (daratumumab) plus bortezomib and dexamethasone as an option for treating relapsed multiple myeloma in people who have had only one pr...

FDA Granted Accelerated Approval to Xpovio Tablets

The U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed ...